Published on 6 Mar 2024 on Zacks via Yahoo Finance
Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
Quanterix Corporation QTRX, a player in ultra-sensitive research products and diagnostics, achieved a significant milestone when the FDA granted a Breakthrough Device designation to its Simoa phospho-Tau 217 (p-Tau 217) blood test for Alzheimer's Disease (AD). The company claims that the p-Tau 217 biomarker is a highly promising tool for accurately diagnosing amyloid pathology.
The FDA’s Breakthrough Device designation is granted to products that have the potential to offer superior diagnosis of life-threatening diseases with an unmet medical need.
Transforming Alzheimer's Diagnostics